Teneligliptin in management of type 2 diabetes mellitus

Surendra Kumar Sharma,1 A Panneerselvam,2 KP Singh,3 Girish Parmar,4 Pradeep Gadge,5 Onkar C Swami6 1Diabetes, Thyroid and Endocrine Centre, Galaxy Speciality Centre, Jaipur, 2Aruna Diabetes Centre, Chennai, 3Fortis Hospital, Sector 62, Phase VIII, Mohali, 4Kokilaben Dhirubhai Ambani Hospital, Andhe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	T2DM Dipeptidyl peptidase 4 inhibitor DPP-4 Inhibitor Teneligliptin India Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/4f1addf81e9043e18e885dc8e2096987
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f1addf81e9043e18e885dc8e2096987
record_format	dspace
spelling	oai:doaj.org-article:4f1addf81e9043e18e885dc8e20969872021-12-02T07:09:09ZTeneligliptin in management of type 2 diabetes mellitus1178-7007https://doaj.org/article/4f1addf81e9043e18e885dc8e20969872016-08-01T00:00:00Zhttps://www.dovepress.com/-teneligliptin-in-management-of-type-2-diabetes-mellitu-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Surendra Kumar Sharma,1 A Panneerselvam,2 KP Singh,3 Girish Parmar,4 Pradeep Gadge,5 Onkar C Swami6 1Diabetes, Thyroid and Endocrine Centre, Galaxy Speciality Centre, Jaipur, 2Aruna Diabetes Centre, Chennai, 3Fortis Hospital, Sector 62, Phase VIII, Mohali, 4Kokilaben Dhirubhai Ambani Hospital, Andheri (W), Mumbai, 5Dr Gadge’s Diabetes Care Centre, Mumbai, 6Unichem Laboratories Ltd, Jogeshwari (W), Mumbai, India Abstract: Teneligliptin is a recently developed oral dipeptidyl peptidase 4 inhibitor indicated for the management of type 2 diabetes mellitus (T2DM) in adults along with diet and exercise. Teneligliptin has been recently available in Japan (Teneria®), Argentina (Teneglucon®), and India (Tenepure; Teneza) at relatively affordable price. This is a positive step toward the management of T2DM in developing countries, where the cost of medicine is out-of-pocket expenditure and is a limiting factor for health care. This review evaluates the efficacy and safety of teneligliptin in the management of T2DM. Teneligliptin has been systematically evaluated in T2DM as monotherapy with diet and exercise and in combination with metformin, glimepiride, pioglitazone, and insulin in short-term (12 weeks) and long-term (52 weeks) studies. These studies have reported a reduction in HbA1c of 0.8%–0.9% within 12 weeks of therapy. Two 52-week studies reported sustained improvement in glycemic control with teneligliptin. Teneligliptin has been found to be well tolerated, and the safety profile is similar to other dipeptidyl peptidase 4 inhibitors. Hypoglycemia and constipation are the main adverse events. Teneligliptin can be administered safely to patients with mild, moderate, or severe renal impairment or end-stage renal disease without dose adjustment. Similarly, it can be used in patients with mild-to-moderate hepatic impairment. Teneligliptin is effective and well tolerated and may have an important role in the management of T2DM. Keywords: diabetes mellitus, dipeptidyl peptidase 4 inhibitor, newer DPP-4 inhibitor, teneligliptin, IndiaSharma SKPanneerselvam ASingh KPParmar GGadge PSwami OCDove Medical PressarticleT2DMDipeptidyl peptidase 4 inhibitorDPP-4 InhibitorTeneligliptinIndiaSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 9, Pp 251-260 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	T2DM Dipeptidyl peptidase 4 inhibitor DPP-4 Inhibitor Teneligliptin India Specialties of internal medicine RC581-951
spellingShingle	T2DM Dipeptidyl peptidase 4 inhibitor DPP-4 Inhibitor Teneligliptin India Specialties of internal medicine RC581-951 Sharma SK Panneerselvam A Singh KP Parmar G Gadge P Swami OC Teneligliptin in management of type 2 diabetes mellitus
description	Surendra Kumar Sharma,1 A Panneerselvam,2 KP Singh,3 Girish Parmar,4 Pradeep Gadge,5 Onkar C Swami6 1Diabetes, Thyroid and Endocrine Centre, Galaxy Speciality Centre, Jaipur, 2Aruna Diabetes Centre, Chennai, 3Fortis Hospital, Sector 62, Phase VIII, Mohali, 4Kokilaben Dhirubhai Ambani Hospital, Andheri (W), Mumbai, 5Dr Gadge’s Diabetes Care Centre, Mumbai, 6Unichem Laboratories Ltd, Jogeshwari (W), Mumbai, India Abstract: Teneligliptin is a recently developed oral dipeptidyl peptidase 4 inhibitor indicated for the management of type 2 diabetes mellitus (T2DM) in adults along with diet and exercise. Teneligliptin has been recently available in Japan (Teneria®), Argentina (Teneglucon®), and India (Tenepure; Teneza) at relatively affordable price. This is a positive step toward the management of T2DM in developing countries, where the cost of medicine is out-of-pocket expenditure and is a limiting factor for health care. This review evaluates the efficacy and safety of teneligliptin in the management of T2DM. Teneligliptin has been systematically evaluated in T2DM as monotherapy with diet and exercise and in combination with metformin, glimepiride, pioglitazone, and insulin in short-term (12 weeks) and long-term (52 weeks) studies. These studies have reported a reduction in HbA1c of 0.8%–0.9% within 12 weeks of therapy. Two 52-week studies reported sustained improvement in glycemic control with teneligliptin. Teneligliptin has been found to be well tolerated, and the safety profile is similar to other dipeptidyl peptidase 4 inhibitors. Hypoglycemia and constipation are the main adverse events. Teneligliptin can be administered safely to patients with mild, moderate, or severe renal impairment or end-stage renal disease without dose adjustment. Similarly, it can be used in patients with mild-to-moderate hepatic impairment. Teneligliptin is effective and well tolerated and may have an important role in the management of T2DM. Keywords: diabetes mellitus, dipeptidyl peptidase 4 inhibitor, newer DPP-4 inhibitor, teneligliptin, India
format	article
author	Sharma SK Panneerselvam A Singh KP Parmar G Gadge P Swami OC
author_facet	Sharma SK Panneerselvam A Singh KP Parmar G Gadge P Swami OC
author_sort	Sharma SK
title	Teneligliptin in management of type 2 diabetes mellitus
title_short	Teneligliptin in management of type 2 diabetes mellitus
title_full	Teneligliptin in management of type 2 diabetes mellitus
title_fullStr	Teneligliptin in management of type 2 diabetes mellitus
title_full_unstemmed	Teneligliptin in management of type 2 diabetes mellitus
title_sort	teneligliptin in management of type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/4f1addf81e9043e18e885dc8e2096987
work_keys_str_mv	AT sharmask teneligliptininmanagementoftype2diabetesmellitus AT panneerselvama teneligliptininmanagementoftype2diabetesmellitus AT singhkp teneligliptininmanagementoftype2diabetesmellitus AT parmarg teneligliptininmanagementoftype2diabetesmellitus AT gadgep teneligliptininmanagementoftype2diabetesmellitus AT swamioc teneligliptininmanagementoftype2diabetesmellitus
_version_	1718399568145547264

Teneligliptin in management of type 2 diabetes mellitus

Ejemplares similares